Trade Regulus Therapeutics Inc. - RGLS CFD
Add to favourite- Summary
- Historical Data
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 2.47 |
Open | 2.44 |
1-Year Change | 92.13% |
Day's Range | 2.44 - 2.85 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
May 1, 2024 | 2.47 | 0.22 | 9.78% | 2.25 | 2.64 | 2.18 |
Apr 30, 2024 | 2.28 | -0.20 | -8.06% | 2.48 | 2.50 | 2.27 |
Apr 29, 2024 | 2.48 | 0.13 | 5.53% | 2.35 | 2.56 | 2.35 |
Apr 26, 2024 | 2.38 | 0.14 | 6.25% | 2.24 | 2.45 | 2.24 |
Apr 25, 2024 | 2.25 | 0.05 | 2.27% | 2.20 | 2.25 | 2.12 |
Apr 24, 2024 | 2.20 | -0.01 | -0.45% | 2.21 | 2.26 | 2.19 |
Apr 23, 2024 | 2.23 | 0.12 | 5.69% | 2.11 | 2.31 | 2.11 |
Apr 22, 2024 | 2.17 | 0.13 | 6.37% | 2.04 | 2.22 | 2.03 |
Apr 19, 2024 | 2.10 | -0.10 | -4.55% | 2.20 | 2.28 | 2.06 |
Apr 18, 2024 | 2.19 | -0.09 | -3.95% | 2.28 | 2.35 | 2.16 |
Apr 17, 2024 | 2.31 | -0.08 | -3.35% | 2.39 | 2.53 | 2.30 |
Apr 16, 2024 | 2.52 | -0.12 | -4.55% | 2.64 | 2.68 | 2.50 |
Apr 15, 2024 | 2.74 | -0.02 | -0.72% | 2.76 | 2.81 | 2.64 |
Apr 12, 2024 | 2.76 | -0.04 | -1.43% | 2.80 | 2.84 | 2.65 |
Apr 11, 2024 | 2.74 | 0.21 | 8.30% | 2.53 | 2.83 | 2.53 |
Apr 10, 2024 | 2.59 | 0.01 | 0.39% | 2.58 | 2.63 | 2.51 |
Apr 9, 2024 | 2.68 | 0.10 | 3.88% | 2.58 | 2.74 | 2.58 |
Apr 8, 2024 | 2.65 | 0.13 | 5.16% | 2.52 | 2.73 | 2.48 |
Apr 5, 2024 | 2.51 | 0.03 | 1.21% | 2.48 | 2.62 | 2.42 |
Apr 4, 2024 | 2.50 | -0.11 | -4.21% | 2.61 | 2.68 | 2.48 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Regulus Therapeutics Inc. Company profile
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Regulus Therapeutics Inc revenues decreased from $10M to $0K. Net loss increased 77% to $27.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects research increase of 16% to $16.5M (expense), general increase of 15% to $7.9M (expense), Stock-based Compensation in SGA increase of 9% to $2.1M (expense).
Equity composition
Common stock $.001 Par, 10/12, 200M auth., 34,130,393 issd. Insider Owns 67.04%.
Industry: | Bio Therapeutic Drugs |
Suite 210
3545 John Hopkins Court
92121
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com